# Replication of the NefIgArd Trial of TRF-budesonide in Primary IgAN

> **NCT06589752** · — · COMPLETED · sponsor: **Ruijin Hospital** · enrollment: 200 (actual)

## Conditions studied

- Primary IgA Nephropathy

## Interventions

- **DRUG:** TARPEYO 4 MG Delayed Release Oral Capsule
- **DRUG:** RAS inhibitor

## Key facts

- **NCT ID:** NCT06589752
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-24
- **Primary completion:** 2024-09-05
- **Final completion:** 2024-09-05
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06589752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06589752, "Replication of the NefIgArd Trial of TRF-budesonide in Primary IgAN". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06589752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*